NICE Rejects Jevtana Because Of Cost, But Clears ALK Abello's Bee Sting Prophylaxis
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.'s cost regulator, NICE, rejects Sanofi's lauded prostate cancer therapy cabazitaxel because it considers it too expensive.